FDA Grants Breakthrough Designation to Calderasib in KRAS NSCLC
29 May 2026 //
BUSINESSWIRE
Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC
11 Jan 2026 //
INDPHARMAPOST
Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX
07 Jan 2026 //
PHARMIWEB

Market Place
Sourcing Support